Key Takeaways

  • 4DMedical (ASX: 4DX) shares were up 5.05% at $4.16 in the Monday 13 July 2026 morning session (20-minute-delayed data, ~11.04am AEST); intraday prices can change through the day.
  • The gain came against the grain: the ASX Health Care sector was down 0.82% that morning and the broader S&P/ASX 200 had slipped 0.18%.
  • No fresh, company-specific announcement was identified in the available material at the time of writing; recent ASX filings were routine share issuances.
  • 4DMedical's half-year to 31 December 2025 showed revenue of A$2.85 million and cash of A$56.8 million, lifted to a pro-forma A$206.2 million by a January 2026 placement and option exercises.
  • The stock has been exceptionally volatile in 2026, trading between $0.23 and $7.55 over the past 52 weeks, and commentary in mid-July placed it roughly 46% below its record high.

Monday morning on the ASX belonged to energy stocks and little else. Fresh United States strikes against Iran over the weekend pushed Brent crude up around 3.3% to roughly US$78.49 a barrel, lifting the Energy sector 0.76% while most of the market drifted lower. The S&P/ASX 200 opened higher but had turned down 0.18% to 8,789.80 by 11.00am AEST, and the Health Care sector was one of the morning's laggards, off 0.82%.

Against that backdrop, 4DMedical Limited (ASX: 4DX) stood out. The Melbourne-based lung-imaging software company climbed 5.05% to $4.16 in the morning session, according to a 20-minute-delayed snapshot taken at about 11.04am AEST, placing it among the strongest gainers on the local market. For a stock that has spent much of 2026 in the headlines for its dramatic price swings, the move puts 4DMedical squarely back in focus.

It is worth stating plainly at the outset: no fresh, company-specific announcement was identified in the available material at the time of writing that would explain the rise. This article therefore separates what is verified from what is plausible, and looks at the company behind one of the ASX's most talked-about healthcare charts.

What Happened to the 4DMedical Share Price

At approximately 11.04am AEST on Monday 13 July 2026, 4DMedical shares were quoted at $4.16, up 5.05% from Friday's close, on 20-minute-delayed data. Because the figures are an intraday snapshot, the percentage gain and price could change materially through the remainder of the session, and the move should not be read as a settled daily result.

The advance is notable for its context rather than its size. Small and mid-cap healthcare names frequently move 5% in a session, but 4DMedical did so on a morning when its own sector fell 0.82% and defensive healthcare peers such as ResMed dropped sharply. Whole-of-market turnover was a modest $859 million or so by 11.04am, meaning relatively small volumes can move individual prices.

The gain also extends a choppy fortnight for the stock. Market data compiled by Yahoo Finance and stockinvest.us showed 4DMedical shares edging about 1% higher to $4.10 on Friday 10 July, after a period of sharp swings in both directions. Financial media outlet The Bull has repeatedly covered the stock's "volatile trading" in recent weeks, including intraday swings of around 15%.

Products and Partnerships: XV LVAS, CT:VQ and the Philips Deal

4DMedical's portfolio spans several regulatory-cleared products. XV LVAS, its foundational lung ventilation analysis software, is cleared by the US Food and Drug Administration (FDA), and CT LVAS applies ventilation analysis to standard CT scans. The most strategically significant product is CT:VQ, which the company says is the world's first non-contrast, CT-based ventilation-perfusion imaging solution. CT:VQ received FDA clearance in September 2025, a European CE Mark in 2026, and Therapeutic Goods Administration (TGA) approval with inclusion on the Australian Register of Therapeutic Goods announced in June 2026, opening its home market.

Reimbursement, the lifeblood of US medtech adoption, has also progressed. According to the company's FY26 half-year report, the US Centers for Medicare and Medicaid Services (CMS) approved reimbursement for XV LVAS at US$299 and CT LVAS at US$650 per scan. Established reimbursement codes materially lower the barrier for hospitals and imaging centres to adopt new technology.

Distribution has been bolstered by a partnership with Royal Philips. Media reports, including from Colitco and Stocks Down Under, described a distribution agreement carrying a guaranteed minimum order commitment of approximately A$15 million (US$10 million) over two years, and Philips lists a 4DMedical CT suite among its healthcare offerings. Coverage has also highlighted the relationship's relevance to the US Department of Veterans Affairs channel, where 4DMedical has long targeted veterans exposed to airborne hazards. The company deepened its US footprint by acquiring Minneapolis-based AI imaging firm Imbio, announced in December 2023, creating what the companies called a comprehensive cardiothoracic image analysis portfolio.

Financial Position: Small Revenue, Substantial Cash

4DMedical's financials remain those of an early-commercial company. Its Appendix 4D and FY26 half-year report, lodged in February 2026, showed revenue from ordinary activities of A$2.85 million for the six months to 31 December 2025, down 1% on the prior corresponding period. That figure underscores how early the commercial story remains relative to the company's multi-billion-dollar market valuation at its 2026 peaks.

The balance sheet is considerably stronger than the revenue line. Cash stood at A$56.8 million at 31 December 2025, and the company reported a pro-forma cash position of A$206.2 million once the net proceeds of its January 2026 placement and associated exercises of listed and unlisted options were included.

A war chest of that size gives 4DMedical a long operating runway and the capacity to fund its US commercial build-out without an imminent return to markets. The trade-off has been dilution: repeated raisings, option exercises and the ongoing issuance of new shares — as seen again in the early-July filings — progressively expand the share count. The half-year report also noted that conditions for the second earn-out payment under the Imbio acquisition were not met, modestly reducing contingent consideration.

Recent Announcements: A Regulatory Hat-Trick, Then Quiet

The first half of calendar 2026 delivered a run of milestones. The CE Mark for CT:VQ opened the European respiratory imaging market, and the June 2026 TGA approval completed a trifecta of clearances across the United States, Europe and Australia for the company's flagship product.

Since the TGA announcement, however, the news flow has been comparatively quiet. July's ASX lodgements have been confined to the routine share issuance and cleansing notices described above. That vacuum of hard news is itself relevant: it means Monday's 5% rise occurred without an identifiable fundamental trigger, leaving sentiment, positioning and technical factors as the more likely — though unverified — drivers.

Sector and Macro Backdrop: Healthcare Lags a Nervy Market

Monday's session was shaped by geopolitics rather than earnings. The US launched a fourth round of strikes in a week against Iran, aimed at protecting shipping in the Strait of Hormuz, and Iran declared the strait closed "until further notice" — a claim US Central Command denied. Brent crude jumped, energy stocks rose, and most other sectors softened. Utilities fell almost 2%, information technology dropped 1.89%, and Health Care declined 0.82%, with ResMed down 4.76% among the larger casualties.

For 4DMedical, the macro backdrop cuts both ways. As a pre-profit growth company, it is sensitive to risk appetite, which tends to deteriorate when geopolitical tension and oil prices rise. Yet its revenue base is unconnected to commodities or shipping lanes, and Monday's move suggests stock-specific dynamics can override a soft sector tape.

Why the Move May Matter

A single morning's 5% move, on delayed intraday data, proves little in isolation. What gives it significance is timing. 4DMedical has been in a pronounced downtrend from its record high, and traders watching the stock will note any sign that selling pressure is exhausting. A rise against a falling sector is one such tentative signal, though it can just as easily reverse.

The move also matters because 4DMedical has become a bellwether for a particular debate on the ASX: how to value pre-revenue-scale medtech with genuine regulatory achievements. Bulls point to a large addressable market, cleared products in three jurisdictions, CMS reimbursement codes and a Philips distribution channel. Bears point to half-year revenue below A$3 million and a valuation that, at its peak, reportedly reached about A$3.6 billion.

The Bull Case: Cleared Products, Reimbursement and Distribution

The constructive view rests on infrastructure now being in place. Regulatory clearance across the US, Europe and Australia removes the binary approval risk that hangs over most small-cap medtech. CMS reimbursement at US$299 and US$650 per scan for XV LVAS and CT LVAS respectively gives US providers a payment pathway, and the Philips agreement — with its reported minimum order commitment — provides a distribution engine far larger than anything 4DMedical could build alone.

The balance sheet strengthens that case. Pro-forma cash above A$200 million means the company can fund commercialisation for years on current spending patterns, reducing near-term financing risk. If scan volumes begin compounding through Philips channels, the Veterans Affairs opportunity and Australian deployment following TGA approval, revenue could inflect from a low base.

The Bear Case: Valuation, Adoption and Dilution Risks

The risks are equally concrete. Revenue of A$2.85 million for a half-year is tiny against a valuation that reached into the billions, meaning the share price capitalises years of flawless execution that has not yet occurred. Hospital adoption of new imaging software is notoriously slow, dependent on clinician workflow change, IT integration and budget cycles, and reported commentary has cautioned that meaningful revenue from recent contract wins may not arrive until later in 2026 or beyond.

Competition is genuine: large imaging incumbents and other AI-imaging developers are investing heavily in functional and AI-assisted lung analysis. Dilution is ongoing, with new shares issued repeatedly through placements and option conversions. The stock's volatility — a 52-week range of $0.23 to $7.55 — is itself a risk, with market commentary noting elevated short interest and 8–10% daily swings becoming commonplace. And while reimbursement codes exist, actual claim volumes and payer behaviour remain unproven at scale.

What Investors May Watch Next

The nearest scheduled milestone is likely the company's Appendix 4C quarterly cash flow report for the June 2026 quarter, typically lodged in late July, which will reveal customer receipts, cash burn and the post-placement cash balance. Investors may also watch for early evidence of orders flowing under the Philips agreement, first commercial CT:VQ deployments in Europe and Australia following the CE Mark and TGA approvals, and any expansion of US reimbursement coverage or Veterans Affairs activity.

Beyond announcements, market-structure signals bear watching: changes in reported short interest, whether the share price can stabilise above recent support levels, and how the stock behaves around the FY26 full-year results expected in August. Any ASX price query, or a company statement clarifying Monday's move, would also be informative.

4DMedical (ASX: 4DX): A Verified Move, an Unverified Reason

The facts of Monday 13 July 2026 are straightforward: 4DMedical shares were up 5.05% at $4.16 at about 11.04am AEST on delayed data, outpacing a healthcare sector down 0.82% and a broader market in mild retreat. The reason is not: no fresh company-specific announcement was identified at the time of writing, and the most defensible explanations — dip-buying after a steep pullback, short-covering, pre-quarterly positioning — remain unproven interpretations.

What is not in doubt is that 4DMedical has assembled regulatory clearances, reimbursement codes, a major distribution partner and a substantial cash balance, while still generating only modest revenue. Whether Monday's rise proves the start of a recovery or another oscillation in an extraordinarily volatile chart will depend on execution evidence that only coming quarters can supply. This article is general information only and does not constitute financial advice; investors should consider their own circumstances and seek professional advice before making decisions.